Foghorn Therapeutics Inc. (FHTX) vs MaxCyte, Inc. (MXCT)
A side-by-side comparison of Foghorn Therapeutics Inc. and MaxCyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FHTX
Foghorn Therapeutics Inc.
$1.93HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
MXCT
MaxCyte, Inc.
$1.06HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
Total return — FHTX vs MXCT
growth of $100 · dividends reinvested · last 5yFHTX -77.9% (-26.1%/yr)MXCT -93.6% (-42.4%/yr)FHTX compounded faster over this window
FHTX MXCT
FHTX vs MXCT: by the numbers
- •MXCT is the larger company ($114M vs $113M market cap).
- •Both run net losses; MXCT's is the smaller (-114.77% vs -175.78% net margin).
- •FHTX grew revenue faster over the past five years (105.83% vs 1.46% CAGR).
Metrics side by side
Valuation
| Metric | FHTX | MXCT |
|---|---|---|
| P/S ratio | 3.08 | 3.66 |
| P/B ratio | N/A | 0.72 |
Profitability
| Metric | FHTX | MXCT |
|---|---|---|
| Gross margin | 89.22% | 79.43% |
| Operating margin | -265.64% | -137.12% |
| Net margin | -175.78% | -114.77% |
| ROE | N/A | -22.45% |
| ROIC | -44.81% | -19.83% |
Growth (annualized)
| Metric | FHTX | MXCT |
|---|---|---|
| Revenue CAGR (5Y) | 105.83% | 1.46% |
| Total return CAGR (5Y) | -31.87% | -37.32% |
Frequently asked
- Which has grown faster, FHTX or MXCT?
- Over the past five years, FHTX grew revenue faster — FHTX at a 105.83% CAGR versus MXCT at 1.46%.
- How have FHTX and MXCT total returns compared?
- Over the past 5 years, FHTX delivered -31.87% and MXCT delivered -37.32% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Foghorn Therapeutics ROEMaxCyte ROEFoghorn Therapeutics operating marginMaxCyte operating marginFoghorn Therapeutics revenue growthMaxCyte revenue growthFoghorn Therapeutics free cash flowMaxCyte free cash flow
Foghorn Therapeutics & MaxCyte appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.